News
Local
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate News
Hot Property
eNewspaper
________________
Subscriptions
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
About Us
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Events
Advertising
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Jobs
CaregiverSD
Community papers
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Games, Puzzles, and Crossword
Crossword
Sudoku
Crossword
Sudoku
Obituaries
Death Notices
Place an obituary
Death Notices
Place an obituary
U-T En Español
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Privacy and Terms
Privacy
Terms
Advertising terms
Privacy
Terms
Advertising terms
Copyright © 2022, The San Diego Union-Tribune |
CA Notice of Collection
|
Do Not Sell My Personal Information
Sections
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate
Obituaries
eNewspaper
Newsletters
Show Search
Search Query
Submit Search
COVID-19
For subscribers
Phenomenal women
Latino life
Crossword
Sudoku
About Us
Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Diego Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sarepta Therapeutics
(NQ:
SRPT
)
126.66
-2.14 (-1.66%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Sarepta Therapeutics
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Got $3,000? 3 Growth Stocks to Double Up On Right Now
January 26, 2024
There's more to stock picking than comparing risk and reward. Finding the right position size for a particular stock is also important.
Via
The Motley Fool
Could Sarepta Therapeutics Become the Next Vertex Pharmaceuticals?
January 25, 2024
It's always tough to be compared to a giant.
Via
The Motley Fool
Why Sarepta Therapeutics Stock Zoomed Nearly 5% Higher Today
January 22, 2024
One pundit feels there is solid potential in one of the company's more recently approved drugs.
Via
The Motley Fool
Catalyst Countdown: 3 Biotech Stocks With Upcoming News That Could Move the Market
January 16, 2024
In the volatile world of biotech stocks, keeping an eye on the news is critical. Here are three companies to look out for.
Via
InvestorPlace
A Closer Look at 14 Analyst Recommendations For Sarepta Therapeutics
January 10, 2024
Via
Benzinga
Stocks Flip To Losses, Nvidia Defies Gravity, Bitcoin Pauses For A Breather: What's Driving Markets Tuesday?
January 09, 2024
Tuesday on Wall Street was marked by a subdued trend in major equity indices as investors remained cautious ahead of key inflation data scheduled for release on Thursday and the kick-off of the...
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
The Latest Analyst Ratings for Sarepta Therapeutics
December 12, 2023
Via
Benzinga
Sarepta Expects Prelim Gene Therapy Revenue To Be $131M In Q4, $200M For Fiscal Year
January 09, 2024
Monday, Sarepta Therapeutics Inc (NASDAQ: SRPT) reported preliminary FY23 net product
Via
Benzinga
Bumble (BMBL) Stock Pops as Elliott Builds a Stake in Rival Match
January 09, 2024
Bumble stock is rising on Tuesday as BMBL investors learn of a $1 billion investment in rival dating services company Match.
Via
InvestorPlace
Why Is Sarepta Therapeutics (SRPT) Stock Up Today?
January 09, 2024
Sarepta Therapeutics stock is rising higher on Tuesday as SRPT investors react to positive comments from company CEO Douglas Ingram.
Via
InvestorPlace
Acuity Brands Posts Upbeat Earnings, Joins Accolade, Urban Outfitters And Other Big Stocks Moving Higher On Tuesday
January 09, 2024
U.S. stocks traded lower, with the Dow Jones index falling over 250 points on Tuesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
2 Growth Stocks That Could Make You Richer in 2024 and Beyond
January 09, 2024
Last year wasn't great for either stock, but that's no reason to ignore them.
Via
The Motley Fool
Could Sarepta Therapeutics Stock Help You Become a Millionaire?
December 09, 2023
Can this struggling stock turn its fortunes around?
Via
The Motley Fool
Analyst Ratings for Sarepta Therapeutics
November 21, 2023
Via
Benzinga
1 Gene Therapy Stock to Buy and Hold for the Long Haul
November 08, 2023
The biotech has what it takes to overcome recent obstacles.
Via
The Motley Fool
5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday
January 08, 2024
The rebound by biopharma stocks in 2023 and the pickup in M&A news flow makes the 2024 JPMorgan Healthcare conference even more interesting.
Via
Benzinga
3 Top Biotech Stocks Worth Adding To Your Portfolio In 2024
January 07, 2024
Given the continuous need for innovative medical treatments, the biotech industry may be a haven despite its inherent volatility and an uncertain macroeconomic environment. Here are three top biotech...
Via
Talk Markets
Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024
January 04, 2024
Needham analyst forecasts positive outlook for Arcellx Inc (ACLX) in 2024, citing potential from pivotal interim readout & strong data from Phase I study, raising price target & adding to Conviction...
Via
Benzinga
3 Things About Sarepta Therapeutics Every Smart Investor Knows
December 28, 2023
Mastering this stock requires appreciating a few scientific nuances.
Via
The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
December 27, 2023
Via
Benzinga
Could Sarepta Therapeutics Be the Next Vertex Pharmaceuticals Stock?
December 22, 2023
Both develop medicines for rare diseases, and each aims to conquer a niche market.
Via
The Motley Fool
1 Revolutionary Stock That Could Make You Richer in 2024 and Beyond
December 17, 2023
Many investors are bailing out, but that might be a mistake.
Via
The Motley Fool
My Take: 4 Strong Growth Stocks to Buy This Week
December 08, 2023
These strong stocks are still available at a great price. That may not be the case a whole lot longer.
Via
The Motley Fool
3 Monster Stocks in the Making
November 18, 2023
These stocks could grow much larger over the next few years.
Via
The Motley Fool
3 Stocks You’ll Regret Not Buying Soon: November 2023
November 16, 2023
These stocks to buy are the ones to scoop up soon for long-term growth as these companies have stable growth catalysts in the coming years.
Via
InvestorPlace
Catalent's Q1 Performance Beat Expectations: Analyst Says Main Focus On Manufacturing Outlook For Sarepta's Gene Therapy
November 15, 2023
Catalent Inc's (NYSE: CTLT) Q1 FY24 revenue of $982 million decreased 4% as reported, or 6%, in constant currency, beating the
Via
Benzinga
Jim Cramer Likes Founder Of AI Company, But Stock Is 'Losing A Fortune' And There's 'Too Much Hype There'
November 15, 2023
On CNBC’s "Mad Money Lightning Round," Jim Cramer said HubSpot, Inc. (NYSE: HUBS) is like a "mini-Salesforce, it’s got incredible growth, and people like growth again.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Is Sarepta Therapeutics Stock a Bad-News Buy?
November 09, 2023
Analysts still expect some sizable returns from the stock.
Via
The Motley Fool
Is It Time to Buy the Nasdaq's 4 Worst-Performing October Stocks?
November 08, 2023
Just because a stock is "on sale" doesn't inherently make it worth purchasing.
Via
The Motley Fool
8 Health Care Stocks Whale Activity In Today's Session
November 07, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.